Related Experiment Video
Updated: Oct 11, 2025

Visualization of Streptococcus pneumoniae within Cardiac Microlesions and Subsequent Cardiac Remodeling
Published on: April 7, 2015
Incidence of Myopericarditis and Myocardial Injury in Coronavirus Disease 2019 Vaccinated Subjects
Rosemary Farahmand1, Caitlin A Trottier2, Joseph P Kannam1
1Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Insights
COVID-19 vaccination may increase myopericarditis risk in men, but not women. Increased myocardial injury rates in 2021 may confound findings. Vaccination benefits outweigh potential risks.
Area of Science:
- Cardiology
- Vaccinology
- Public Health
Background:
- Recent reports suggest a link between coronavirus disease 2019 (COVID-19) vaccination and myopericarditis.
- The causal relationship between COVID-19 vaccination and myopericarditis remains unclear, with potential confounding factors.
Purpose of the Study:
- To investigate the association between COVID-19 vaccination and myopericarditis incidence.
- To compare gender-specific cumulative incidence rates of myopericarditis and myocardial injury before and after COVID-19 vaccination.
Main Methods:
- A cohort study compared myopericarditis and myocardial injury incidence in vaccinated patients in 2021 with the same cohort from 2019.
- Gender-specific incidence rates were analyzed, adjusting for age.
Main Results:
- The incidence of myopericarditis was significantly higher in vaccinated men compared to the control group (rate ratio 9.7, p=0.04).
- No significant difference in myopericarditis incidence was observed in vaccinated women compared to controls (rate ratio 1.28, p=0.71).
- Increased rates of myocardial injury were noted in both men and women in 2021 compared to 2019, irrespective of vaccination status.
Conclusions:
- The study indicates a potential increase in myopericarditis diagnosis post-COVID-19 vaccination among men, but not women.
- Increased myocardial injury rates in 2021 may influence the observed myopericarditis diagnoses, suggesting potential confounding factors.
- The established benefits of COVID-19 vaccination for individual and public health are considered to exceed the potential small risk of myopericarditis.
Abstract:
Several recent publications have described myopericarditis cases after the coronavirus disease 2019 (COVID-19) vaccination. However, it is uncertain if these cases occurred secondary to the vaccination or more common etiologies of myopericarditis. To help determine whether a correlation exists between COVID-19 vaccination and myopericarditis, the present study compared the gender-specific cumulative incidence of myopericarditis and myocardial injury in a cohort of COVID-19 vaccinated patients at a tertiary care center in 2021 with the cumulative incidence of these conditions in the same subjects exactly 2 years earlier. We found that the age-adjusted incidence rate of myopericarditis in men was higher in the vaccinated than the control population, rate ratio 9.7 (p = 0.04). However, the age-adjusted incidence rate of myopericarditis in women was no different between the vaccinated and control populations, rate ratio 1.28 (p = 0.71). We further found that the rate of myocardial injury was higher in both men and women in 2021 than in 2019 both before and after vaccination, suggesting that some of the apparent increase in the diagnosis of myopericarditis after vaccination may be attributable to factors unrelated to the COVID-19 vaccinations. In conclusion, our study reaffirms the apparent increase in the diagnosis of myopericarditis after COVID-19 vaccination in men but not in women, although this finding may be confounded by increased rates of myocardial injury in 2021. The benefits of COVID-19 vaccination to individual and public health clearly outweigh the small potential increased risk of myopericarditis after vaccination.
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis I: Introduction
Pericarditis I: Introduction
Pericarditis II: Clinical Features and Diagnostic Tests
Pericarditis III: Medical Management

